Avenue Therapeutics, Inc. Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
3Avenue rapeutics's Business Model
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
About Avenue rapeutics
Website: https://www.avenuetx.com
CEO (Chief Executive Officer): Dr. Alexandra MacLean M.D.
IPO date: 2017-06-27
Contact
Country: US
Address: 1140 Avenue of the America
City: New York
State: NY
Phone: 781 652 4500
Zip Code: 10036
Other
CIK: 0001644963
ISIN: US05360L3042
CUSIP: 05360L205
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
